CTOR Key Statistics, Chart & Performance
The current stock price of CTOR is 1.12 USD. In the past month the price decreased by -34.88%. In the past year, price increased by 21.86%.
CTOR Latest News, Press Relases and Analysis
CTOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About CTOR
Company Profile
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Company Info
CITIUS ONCOLOGY INC
11 Commerce Drive, 1St Floor
Cranford NEW JERSEY US
Employees: 0
Phone: 19089676677
CITIUS ONCOLOGY INC / CTOR FAQ
What does CITIUS ONCOLOGY INC do?
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Can you provide the latest stock price for CITIUS ONCOLOGY INC?
The current stock price of CTOR is 1.12 USD. The price decreased by -0.88% in the last trading session.
Does CITIUS ONCOLOGY INC pay dividends?
CTOR does not pay a dividend.
How is the ChartMill rating for CITIUS ONCOLOGY INC?
CTOR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CTOR stock?
7 analysts have analysed CTOR and the average price target is 6.12 USD. This implies a price increase of 446.43% is expected in the next year compared to the current price of 1.12.
Should I buy CTOR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTOR.
What is the Short Interest ratio of CITIUS ONCOLOGY INC (CTOR) stock?
The outstanding short interest for CITIUS ONCOLOGY INC (CTOR) is 2.66% of its float.
CTOR Technical Analysis
CTOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTOR. Both the profitability and financial health of CTOR have multiple concerns.
CTOR Financial Highlights
Over the last trailing twelve months CTOR reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -74.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.54% | ||
| ROE | -128.91% | ||
| Debt/Equity | 0.12 |
CTOR Forecast & Estimates
7 analysts have analysed CTOR and the average price target is 6.12 USD. This implies a price increase of 446.43% is expected in the next year compared to the current price of 1.12.